Will the dark sky over advanced renal cell carcinoma soon become brighter?
Until recently, immunotherapy has been the most efficient treatment for advanced renal cell carcinoma, but clinical results are largely unsatisfactory. More promising agents are being developed as a result of an improved understanding of the biology of the disease. Several agents that target known biological abnormalities of the disease are now being tested in the clinic. This review describes the encouraging clinical results obtained to date with these new drugs or combinations of drugs.
D'Hondt
V
V
Clinic of Medical Oncology, Institut Jules Bordet, Bd de Waterloo 125, Brussels 1000, Belgium.
Gil
T
T
Lalami
Y
Y
Piccart
M
M
Awada
Ahmad
A
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007680:Kidney Neoplasms / Q000188:drug therapy*; D017978:Receptors, Growth Factor / Q000037:antagonists & inhibitors; D015398:Signal Transduction / Q000187:drug effects; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D017978:Receptors, Growth Factor